Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Recurrence 1Neoplasm, Residual 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1

Interventions

Cyclophosphamide 65Rituximab 62fludarabine 40Etoposide 25Lenalidomide 19fludarabine phosphate 17Immunotherapy, Adoptive 17Doxorubicin 17Cytarabine 17Vincristine 15Magnetic Resonance Spectroscopy 14Prednisone 13pembrolizumab 11Specimen Handling 11Dexamethasone 10CT-P10 10Melphalan 9Carmustine 9Carboplatin 9Bortezomib 9Bendamustine Hydrochloride 9obinutuzumab 8ibrutinib 8Mycophenolic Acid 8Biopsy 8Radiotherapy 7Ifosfamide 7polatuzumab vedotin 6Whole-Body Irradiation 6Methotrexate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell × tisagenlecleucel × Clear all
NCT04419909 2025-07-02

Retreatment With CTL019/CTL119

University of Pennsylvania

Phase 1 Not yet recruiting
12 enrolled
Lymphoid

Lymphoma, B-Cell

NCT04234061 2024-11-07

TARMAC

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡